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Abstract
Self-sampling could increase cervical cancer screening uptake. While methods have been identified for human
papillomavirus (HPV) testing, to date, self-sampling has not provided adequate specimens for cytology. We piloted the
validity and reliability of using a self-lavaging device for cervical cytology and HPV testing. We enrolled 198 women in New
York City in 2008–2009 from three ambulatory clinics where they received cervical cancer screening. All were asked to use
the Delphi ScreenerTM to self-lavage 1–3 months after clinician-collected index cytological smear (100 normal; 98 abnormal).
Women with abnormal cytology results from either specimen underwent colposcopy; 10 women with normal results from
both specimens also underwent colposcopy. We calculated sensitivity of self-collected cytology to detect histologically
confirmed high grade lesions (cervical intraepithelial neoplasia, CIN, 2+); specificity for histology-negative (CIN 1 or lower),
paired cytology negative, or a third cytology negative; and kappa for paired results. One hundred and ninety-seven (99.5%)
women self-collected a lavage. Seventy-five percent had moderate to excellent cellularity, two specimens were
unsatisfactory for cytology. Seven of 167 (4%) women with definitive results had CIN2+; one had normal and six abnormal
cytology results with the self-lavage (sensitivity = 86%, 95% Confidence Interval, CI: 42, 100). The kappa for paired cytology
was low (0.36; 95% CI: 0.25, 0.47) primarily due to clinician specimens with atypical squamous cells of undetermined
significance (ASC-US) and low grade squamous intraepithelial lesion (LSIL) coded as normal using Screener specimens.
However, three cases of HSIL were coded as ASC-US and one as normal using Screener specimens. Seventy-three women
had paired high-risk HPV tests with a kappa of 0.66 (95% CI: 0.49, 0.84). Based on these preliminary findings, a larger study to
estimate the performance of the Screener for co-testing cytology and HPV or for HPV testing with cytology triage is
warranted.
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Introduction
Approximately 50% of women enrolled in one of seven large
private insurance plans and diagnosed with cervical cancer
between 1995 and 2000 in the United States (US) had not been
screened in the three years prior to diagnosis [1]. Under-screening
is likely to be higher among uninsured women. Finding innovative
ways to screen for cervical cancer could improve uptake among
under-screened populations.
Offering self-sampling, in place of a pelvic examination, which
some women find embarrassing or uncomfortable [2,3], could
increase screening uptake. A number of self-sampling methods
such as tampon and swab provide valid specimens for human
papillomavirus (HPV) tests [4–6]; however, to date, self-sampling
has not been found to provide adequate specimens for cytology
[7].
HPV tests will be increasingly used as the primary screening test
[8], but cytology will continue to play a role. HPV tests are not
useful for women under age 30 [8], given their high prevalence of
transient infections [9]. Further, cytology can be used for triage of
HPV-positive cases with its higher specificity until new diagnostics
are fully developed [10]. Identifying a self-sampling method that
can be used for both HPV testing and cytology is thus important
for optimizing self-sampling options.
We piloted the validity and reliability of using a self-lavaging
device, the Delphi ScreenerTM (Delphi Bioscience, Scherpenzeel,
Netherlands), for cervical cytology by comparing paired self- and
clinician-obtained specimens using liquid-based cytology (LBC)
among 198 women, and high-risk HPV in a sub-sample.
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Materials and Methods
The protocol for this study and supporting Standards for
reporting of Diagnostic Accuracy (STARD) checklist are available
as supporting information (see Protocol S1 and Checklist S1).
Recruitment and study visit
From December 1, 2008 to August 31, 2009, we enrolled 198
women who had attended one of three ambulatory clinics at the
New York Presbyterian Hospital (NYPH) for cervical cancer
screening. Clinicians at these three clinics asked women receiving
cervical cancer screening as part of standard clinical care for
permission to share their contact information with recruiters.
Recruiters phoned a convenience sample of consenting women to
schedule study visits or record reasons for ineligibility or declining
participation. During the pre-study index visit, women underwent
a standard pelvic examination with clinician-collected liquid based
cytology (LBC), and HPV testing if ordered by the clinician.
Recruiters scheduled study enrollment visits 1–3 months after
the index visit. One month after the index cytology results should
have allowed sufficient time for cervical cells to replenish, with an
upper limit of three months to minimize the potential for true
changes in cervical cytology. By design, half of the participants had
normal and half abnormal cytology results at the index visit to
achieve the required sample size of 100 in each group. We used
atypical squamous cells of undetermined significance (ASC-US) or
worse to define abnormal cytology as these diagnoses trigger
clinical follow-up [11]. Women whose index cervical screening
results included co-testing with HPV were also co-tested with HPV
using the Delphi Screener specimen. To be eligible, women
needed to be at least 18 years old. Women were excluded if they
reported current pregnancy, breastfeeding, hysterectomy, or
discomfort reading on their own in Spanish or English. Women
were asked not to schedule an appointment if they were within 4
days of the first day of their menses, or if they had undergone
colposcopy prior to the study visit, as colposcopy and biopsy could
change cytological results.
All participants provided written informed consent and received
a packaged Screener for use in a private room at the clinical
research site along with pictorial user instructions (which were also
on the wall of the room in poster format). Study interviewers
reviewed instructions with participants before they used the
Screener on their own in a private room. The Delphi Screener
is a sterile, plastic, syringe-like device containing 5 mL of buffered
saline for self-lavage. The Screener currently does not have US
Food and Drug Administration clearance. Columbia University’s
institutional review board approved use of the device as
investigational with non-significant risk (ClinicalTrials.gov
NCT00702208). Study implementation followed the ethical
standards of the Declaration of Helsinki. Study visits during
which women collected the self-lavage specimens took approxi-
mately 30–60 minutes and women received $30 to reimburse
them for their time. Women were not reimbursed for follow-up
visits that were part of their standard clinical care.
Specimen handling
Staff delivered specimens to the laboratory within 24 hours.
Laboratory staff centrifuged specimens at 1700 rpm for five
minutes, pouring off the supernatant, and pipetting the cell pellet
into a Cytyc PreservCyt ThinPrep vial with 20 mL of PreservCyt
(Hologic, Marlborough, MA). Stability testing on nine pre-test
specimens found no decrease in cellular integrity at 24 or 48 hours
after receipt in the laboratory. Based on this stability testing,
centrifugation and fixing was batched and completed within
72 hours of self-collection (up to 24 hours for delivery to the
laboratory plus up to 48 hours from receipt to processing).
After suspension in PreservCyt, specimens were processed per
manufacturing guidelines for ThinPrep specimens. Participants
whose index screening included co-testing for HPV were co-tested
using the Screener specimen with the Hybrid Capture II (Qiagen,
Hilden, Germany) test per manufacturer specifications with a cut-
off of one relative light unit.
Cytotechnologists used the 2001 Bethesda classification system
[12] and recorded amount of fluid collected, cellularity, and
presence of transformation zone cells (defined as endocervical
and/or metaplastic cells). Each sample was reviewed by two
cytotechnologists blinded to one another’s diagnosis. These same
cytotechnologists diagnosed all of the specimens collected using the
self-lavage specimen. Abnormal slides were referred to a cytopa-
thologist for final diagnosis. Cytotechnologists and cytopathologists
were blinded to index results.
Clinical follow-up
Participants with abnormal cytology result either from the pre-
study index visit with standard clinician collection or using the self-
lavaging device as part of the study were invited for colposcopy.
Ascertainment bias occurs when only people with positive
screening results are brought back for further diagnosis. Ten
women (10%) with normal cytology results using both specimens
were also invited for colposcopy to estimate ascertainment bias;
these women received an additional $30 for this visit. Colposcopy
was performed at three sites. All sites collected biopsies of
acetowhite lesions. One site routinely collected endocervical
curettings (ECCs), one collected ECC if no biopsy was taken,
and one collected ECC if visualization of the transformation zone
was incomplete, reflecting the lack of consensus on ECC utility
when the transformation zone is fully visualized [13]. Women
were followed through January 25, 2010.
Sample size
The sample size was originally calculated using the index
cytological smear as the gold standard; 98 women with normal/
abnormal results would detect a sensitivity/specificity of 80% with
a lower 95% confidence limit of 65% [14]. As cytology is known to
have limited sensitivity [15], however, results from two or more
biopsies should be used to define true precursors to cervical cancer
[16]. Our pilot, proof-of-concept study was not powered based on
biopsy results; seven participants had histologically confirmed
high-grade lesions resulting in 29% power to detect a sensitivity of
80% with a lower 95% confidence limit of 65%.
Statistical analyses
We calculated kappa statistics for clinician- and self-collected
specimens for cytology and for HPV and estimated sensitivity and
specificity, using colposcopy endpoints as the gold standard to
define true cases. For this gold standard, true positives were
defined as histologically confirmed high-grade cervical intraepi-
thelial neoplasia (CIN2+) from biopsy or ECC. True negatives
were defined as women who: 1. had normal cytology with both
specimens but no colposcopy (n = 83); 2. had normal findings
during colposcopy visit (defined as negative or low-grade biopsy/
ECC or satisfactory colposcopy with no acetowhite lesions
visualized, n= 70); or 3. missed colposcopy, but had normal
repeat cytology after 6 months or more at the index clinic if ASC-
US or low grade squamous intraepithelial lesions (LSIL) at index
visit (n = 7). None of the ten women with normal results who
underwent colposcopy to estimate ascertainment bias had
abnormalities. Given that colposcopy was not used to confirm all
Use of Self-Lavage for Cervical Cancer Screening
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negatives, we include adjusted estimates assuming that 1% of
women [17] who had normal cytology with both specimens were
missed cases of CIN2+. Additionally, we calculated secondary
sensitivity and specificity estimates including CIN1 as true
positives. We calculated 95% confidence intervals for sensitivity
and specificity estimates using exact confidence intervals based on
binomial probabilities.
We compared index cytology result by clinic, age and sexual
activity. We compared age and initial cytology result of women
who enrolled to those who refused or missed scheduled
appointments and of the 167 women with validity results to those
missing results. We used Fisher’s exact tests to compare categorical
outcomes and the Kruskal-Wallis test for non-parametric data to
compare continuous outcomes. Analyses were conducted in Stata
(StataCorp, College Station, TX).
Results
During recruitment months, 5,509 women underwent cytolog-
ical screening at participating clinics and 5,479 had sufficient
samples. Of these women, 198 (3.6%) eligible women enrolled,
202 (3.7%) declined participation, 122 (2.2%) missed their study
appointment, 18 were ineligible (0.3%) and most (4,939, 90.1%)
were never invited to participate in this convenience sample
(Figure S1). Thus 38% of those invited declined participation,
primarily citing lack of time as their reason, and an additional 23%
did not come to their study visit.
The majority of women were Latina (85%) and sexually active
in the last month (76%) with a median age of 31 (Table 1).
Nineteen percent of the participants were post-menopausal.
Women with normal index cytology results using clinician-
collected specimens were older than women with abnormal
cytology (median age of 42 versus 24 years respectively, p,.001,
Table 1). This pattern remained using the self-lavage cytology
results; the median age for women with normal results on self-
lavage was 32 versus 24 years for women with abnormal cytology,
p = 0.01. Among the 98 women with abnormal cytology results, 54
(55%) had LSIL, 38 (39%) ASC-US, 4 (4%) high grade squamous
intraepithelial lesion (HSIL), one (1%) atypical squamous cell
cannot rule out HSIL (ASC-H) and one (1%) atypical glandular
cells (AGC). The distribution of all abnormal results from
participating clinics during recruitment months (n = 870) was
similar: 46% LSIL, 48% ASC-US, 3% HSIL, 2% ASC-H and 1%
AGC. Women who refused or missed their appointment were
similar to participants for index cytology results, HPV results, and
age. Women with missing versus definitive results (Figure S1) were
also similar by age, index HPV, and index cytology. Results from
colposcopy were used for definitive diagnosis for 46% (77/167) of
women. The median time between index visit and colposcopy was
127 days (interquartile range, IQR: 69, 260).
Specimen collection and quality
Only one morbidly obese participant was unable to self-lavage,
resulting in 197 specimens. The median fluid collected was
1.0 mL, ranging from 0.1 to 5.0 mL. Cytotechnologists coded
75% of specimens as having moderate to excellent cellularity, 23%
low cellularity and 2% scant. Two of the Screener specimens (1%)
were unsatisfactory for cytology, compared to 0.5% (30/5509) of
clinician-collected specimens from participating clinics during the
same time period (z-test, p = 0.51). A total of 195 self-lavage
specimens were collected and readable for cytology.
The median number of days between clinician- and self-
collected specimens was 60 days; the median for women whose
index cytology was normal was longer than women with abnormal
results (65 versus 55 days respectively, p = 0.02). Transformation
zone cells were present on 93% of clinician-collected specimens
compared to 18% of Screener specimens (p,.001). Transforma-
tion zone cells were less likely to be present using clinician-
collected specimens for post-menopausal women: 81% of 38 post-
menopausal women had transformation zone cells compared to
96% of 159 menopausal women (p = 0.006). However, the reverse
was true using self-lavage specimens, 26% of the post-menopausal
specimens showed transformation zone cells compared to 16% of
the menopausal women (p = 0.01).
Delphi Screener specimens for cytology and HPV
Most women (92/99, 93%) whose index cytology was normal
were diagnosed as normal using the Screener (Table 2). Paired
specimens for dichotomous cytology results showed 68% overall
agreement, with a kappa of 0.36 (95% Confidence Interval, CI:
0.25, 0.47). This result did not change when limited to women
with 28–60 days between specimen collections (n = 93, kap-
pa= 0.38, 95% CI: 0.21, 0.55). However, agreement was greater
for women over the age of 30 (n= 99, kappa= 0.48, 95% CI: 0.29,
0.67) than for women aged 30 and under (n = 97, kappa= 0.20,
95% CI: 0.07, 0.34).
As seen in Figure S1, 167 women were included in the estimates
of sensitivity and specificity; 28 women with valid Screener
cytology results did not come for their scheduled colposcopy visit
or had unsatisfactory colposcopy results. Seven women had
histologically confirmed high-grade lesions; all had abnormal
clinician-collected cytology: one HSIL, four LSIL, one ASC-H
and one ASC-US. Five of seven had identical self-collected
cytology results. One woman diagnosed as HSIL using the
clinician-collected specimen was diagnosed with ASC-US using
the Screener specimen and one diagnosed as ASC-US was
diagnosed as normal with the Screener.
Using unadjusted data, clinician-collected cytology had a 7/7 or
100% sensitivity (97.5% CI: 59, 100) and a specificity of 93/160 or
58% (95% CIs: 50, 66), while the Screener had a sensitivity of 6/7,
86% (95% CIs: 42, 100) and a specificity of 128/160, 80% (95%
CIs: 73, 96) to identify CIN 2+ (Table 3). Adjusting for
ascertainment bias, the sensitivities are 87% (95% CIs: 47, 100)
for clinician-collected cytology and 75% (95% CIs: 35, 97) for self-
lavage cytology; the specificities are 58% (95% CIs: 50, 66) and
80% (95% CIs: 73, 86) respectively.
Including histologically confirmed CIN1 as true positives does
not change these results substantially. Fifteen cases of low-grade
histology were identified; all fifteen had abnormal cytology using
the clinician-collected specimen (twelve LSIL, two ASC-US, one
HSIL) and eleven had abnormal cytology using the Screener (six
LSIL, five ASC-US). For the clinician-collected specimens, this
definition results in a sensitivity of 22/22, or 100% (97.5% CI: 85,
100) and specificity of 52/145, or 64% (95% CI: 56, 72). For
Screener specimens, using this definition, sensitivity is 17/22, 77%
(95% CI: 55, 92) and specificity is 124/145, 86% (95% CI: 79, 91).
Seventy-six Screener specimens (39%) were co-tested for HPV.
Two (3%) were insufficient for HPV diagnosis, compared to 9%
(174/1918) for clinician-collected specimens during the same time
period (z-test, p = 0.03). Overall HPV agreement between
clinician- and self-collected specimens was 84% with a kappa of
0.66 (95% CIs: 0.49, 0.84, Table 2).
Discussion
Delphi Screener specimens showed moderate to high cellularity
and comparable rates of sufficient specimens to clinician-collected
specimens for cytology and HPV. The main difference in
Use of Self-Lavage for Cervical Cancer Screening
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Table 1. Demographic, sexual history and clinical characteristics by index cytology result; validity and reliability of the Delphi
Screener for cervical cancer screening, New York City, 2009.
Characteristics Index cytology result Total (N=198) p-value*
Normal (n =100) Abnormal (n =98)
Self-reported race ethnicity, n(%)** 0.06
Latina/Hispanic 81 (82.7) 85 (87.6) 166 (85.1)
African American/Black 17 (17.3) 8 (8.3) 25 (12.8)
Other 0 (0.0) 4 (4.1) 4 (2.0)
Median age in years 42 24 31 0.00
(IQR/range) (29–49/18–65) (22–32/18–72) (23–45/18–72)
Time of last sex, n(%)*** 0.11
Within the last month 69 (69.7) 81 (82.6) 150 (76.1)
Within the last year 14 (14.1) 8 (8.2) 22 (11.2)
More than a year ago 16 (16.2) 9 (9.2) 25 (12.7)
Post-menopausal, n (%)*** 30 (30.3) 8 (8.2) 38 (19.3) 0.00
Clinician-collected cytological result, n (%) na
Normal 100 (100.0) 0 (0.0) 100 (50.0)
ASC-US 0 (0.0) 38 (38.8) 38 (19.2)
LSIL 0 (0.0) 54 (55.1) 54 (27.3)
ASC-H 0 (0.0) 1 (1.0) 1 (0.5)
AGC 0 (0.0) 1 (1.0) 1 (0.5)
HSIL 0 (0.0) 4 (4.1) 4 (2.0)
Clinician-collected HPV result, n (%) 0.00
Positive 4 (4.0) 26 (26.5) 30 (15.2)
Negative 42 (42.0) 4 (4.1) 44 (23.2)
Insufficient specimen 1 (1.0) 5 (5.1) 6 (3.0)
Not done 53 (53.0) 63 (64.3) 116 (58.6)
Self-sampled cytological result, n (%) 0.00
Normal 92 (92.0) 55 (56.1) 147 (74.2)
ASC-US 4 (4.0) 14 (14.3) 18 (9.1)
LSIL 1 (1.0) 26 (26.5) 27 (13.6)
ASC-H 2 (2.0) 1 (1.0) 3 (1.5)
AGC 0 (0.0) 0 (0.0) 0 (0.0)
HSIL 0 (0.0) 0 (0.0) 0 (0.0)
Insufficient specimen/not collected 1 (1.0) 2 (2.0) 3 (1.5)
Self-sampled HPV result, n (%) 0.00
Positive 9 (9.0) 24 (24.5) 33 (16.7)
Negative 34 (34.0) 7 (7.1) 41 (20.7)
Insufficient specimen 2 (2.0) 0 (0.0) 2 (1.0)
Not done 55 (55.0) 67 (68.4) 122 (61.6)
Colposcopy result, n (%) 0.00
CIN 2+ 0 (0.0) 7 (7.1) 7 (3.5)
CIN 1 0 (0.0) 15 (15.3) 15 (7.6)
Normal histology (biopsy/ECC) 5 (5.0) 35 (35.7) 40 (20.2)
Normal colposcopy, no histology 5 (5.0) 10 (10.2) 15 (7.6)
Not done (normal cytology/HPV) 83 (83.0) 7 (7.1)**** 90 (45.5)
Insufficient biopsy specimen 5 (5.0) 2 (2.0) 7 (3.5)
Loss to follow-up 1 (1.0) 20 (20.4) 21 (10.6)
No/unsatisfactory lavage result 1 (1.0) 2 (2.0) 3 (1.5)
na = not applicable; IQR = interquartile range; HPV= human papillomavirus; ASC-US = atypical squamous cells of undetermined significance; ASC-H = atypical squamous
cells cannot rule out high grade; LSIL = low grade squamous intraepithelial lesion; AGC= atypical glandular cells; HSIL = high grade squamous intraepithelial lesion;
CIN = cervical intraepithelial lesion; ECC = endocervical curetting.
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specimen quality was the presence of transformation zone cells:
over 90% of clinician-collected specimens contained these cells
compared to 18% of Screener specimens. Cross-sectional studies
have found an association between presence of these cells,
especially endocervical cells, and concurrent abnormal cytological
findings [18]. Longitudinal studies, however, have found no
association between the absence of transformation zone cells
among women with negative cytology and subsequent high grade
lesions [19,20]. Furthermore, the validity of HPV testing is
independent of the presence of transformation zone cells [21].
Therefore, the absence of these cells may not be an important
indicator of specimen quality for use in cervical cancer screening.
However, the utility of transformation zone cells for women 30
years of age and under has not been well-studied.
Agreement between the clinician- and Screener-collected
cytology result was low (kappa= 0.36), primarily due to women
with ASC-US and LSIL from clinician-collected specimens
diagnosed as normal using Screener specimens. Agreement for
cervical cytology with clinician-collected specimens also tend to be
low; one study reported kappas of 0.26 to 0.40 among six
cytologists reading the same 70 slides for specimen adequacy alone
[22]. Another study of 117 abnormal slides, found kappas of 0.39
to 0.57 among seven cytologists, depending on classification system
used [23]. The fairly low kappa in this study may be an indicator
of low reliability for cervical cytology in general rather than low
reliability from using the Screener specimen, although a larger
study is needed to ensure that high grade cases are not
systematically missed.
As expected women who had abnormal cytology results
(primarily ASC-US and LSIL) were, on average, younger than
women with normal cytology results. The kappa for cytology
improved with older age, as would be anticipated given fewer
abnormal findings. Future studies should be designed to produce
separate estimates of the performance of self-lavage for women
aged 30 years and under versus over 30.
Agreement of high-risk HPV testing between the Screener and
clinician-collected specimen was moderate (kappa= 0.66), and
comparable to an earlier study using the GP5+/6+ polymerase
chain reaction HPV test with the Screener (kappa= 0.71) [24].
These findings are also similar to estimates for self-collected
tampons or swabs for HPV testing in a recent meta-analysis
(kappa = 0.66) [6], suggesting the Screener is comparable to other
self-sampling methods for high-risk HPV testing.
Clinically, more important than agreement between the two
specimens is their ability to detect abnormalities in women with
CIN2+. Our preliminary point estimate of the sensitivity of the
Screener using cytology was good even after adjusting for possible
ascertainment bias (75.0%), although the 95% confidence interval
was wide with a lower bound of 35%. The point estimate for the
specificity of the Screener specimen for cytology was higher than
that of clinician-collected specimens. While these preliminary
estimates are promising, a larger study is needed to better estimate
Table 2. Number of women with results from index clinician-collected specimens by results from Screener specimen and kappa
statistic; validity and reliability of the Delphi Screener for cervical cancer screening, New York City, 2009.
Cytology result using clincian-collected specimen (n=195*)
Cytology result using Screener specimen Normal ASC-US LSIL ASC-H AGC HSIL
Normal 92 28 25 0 1 1
ASC-US 4 3 8 0 0 3
LSIL 1 6 20 0 0 0
ASC-H 2 0 0 1 0 0
AGC 0 0 0 0 0 0
HSIL 0 0 0 0 0 0
Weighted kappa** 0.34
(95% CI) (0.24, 0.45)
HPV result using Digene Hybrid Capture II (n =73***)
HPV result using Screener specimen HPV negative HPV positive
HPV negative 36 5
HPV positive 7 25
Kappa 0.66
(95% CI) (0.49, 0.84)
CI = confidence interval; HPV =human papillomavirus; ASC-US = atypical squamous cells of undetermined significance; ASC-H= atypical squamous cells cannot rule out
high grade; LSIL = low grade squamous intraepithelial lesion; AGC= atypical glandular cells; HSIL = high grade squamous intraepithelial lesion.
*Excluding 2 unsatisfactory specimens, 1 originally ASC-US/1 originally LSIL.
**Weighted Kappa was calculated by combining ASC-H, AGC, and HSIL into uppermost category, and assuming 1 point difference between each category.
***1 specimen was unsatisfactory using clinician specimen, 2 specimens were unsatisfactory using Screener specimen.
doi:10.1371/journal.pone.0082115.t002
*p-values are calculated using the Fisher’s exact tests to compare proportions and the Kruskal Wallis test to compare medians.
**N = 195, missing data on two women with normal and one with abnormal index cytology.
***N = 197, one woman with normal index cytology missing all demographic data other than age.
****Received a second clinician-collected cytology test per standard clinical care which was normal.
doi:10.1371/journal.pone.0082115.t001
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the extent to which high grade cases might be missed before
relying on a Screener specimen alone for cytology.
The idea to use self-lavage for cytology is not new. In the 1960s,
a number of studies tested the use of the Davis cytopipette or
irrigation smear for self-lavage for cytological smears [25–29].
While initial results were promising [26], ultimately high
proportions of unsatisfactory specimens, as high as 37% [29],
coupled with low sensitivity, prohibited further use of the device in
cervical cancer screening. In one study, 5 of 13 histologically
confirmed cervical cancer cases tested negative using the irrigation
smear [29]. In the current study, however, six of the 7
histologically confirmed cases of CIN2+ and 11 of the 15
histologically confirmed cases of CIN1 had abnormal cytology
results using the self-lavage, suggesting further study of the
Screener for cytology is warranted. Further, most women (79%)
reported preferring self-lavage over clinician-collection for future
cervical cancer screening [30].
The present study had a number of limitations. The study was
not sufficiently powered based on colposcopy results for endpoints;
this study tested proof-of-concept for use of Screener self-lavage
specimens for cervical cytology. Colposcopy was not used on all
women, and sixteen women who received colposcopy did not have
a specimen taken for histology. Additionally women were not
followed for a sufficiently long time to produce robust specificity
estimates; clearly some high grade lesions may have been
missed. Missing more than 1% of negatives is highly unlikely in
this low-risk population however, and adjusted sensitivity and
specificity calculations for the Screener specimen remain reason-
able. Finally, while the same two cytotechnologists diagnosed all of
the self-lavage specimens, index clinician-collected specimens were
diagnosed by a larger pool of cytotechnologists available at the
hospital laboratory; some disagreements in cytological findings
could be caused by this difference in cytotechnologists.
Despite the low reliability of cytology between clinician- and
self-collected specimens, most high-grade lesions were caught and
reliability of HPV testing was good. A larger study to estimate the
performance of the Screener for HPV testing with cytology triage
or co-testing is warranted and could result in identifying an
important new tool to increase cervical cancer screening uptake in
hard-to-reach populations. Cost of the device would also need to
be considered prior to large-scale introduction.
Supporting Information
Figure S1 Participant flow; validity and reliability of the
Delphi Screener for cervical cancer screening, New York
City, 2009.
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cytology testing among low income women in New York
Table 3. Sensitivity and specificity of cytology for clinician-collected and Screener specimens; validity and reliability of the Delphi
Screener for cervical cancer screening, New York City, 2009.
Colposcopy/repeat cytology (n =167)
Unadjusted High grade (CIN 2+) Normal




(95% CI)* (59.0, 100)** (50.0, 65.9)




(95% CI)* (42.1, 99.6) (72.9, 85.9)
Adjusted for ascertainment bias***




(95% CI)* (47.3, 99.7) (49.8, 65.7)




(95% CI)* (34.9, 96.8) (72.8, 85.8)
CI = confidence interval.
*95% Confidence intervals are calculated using exact confidence intervals based on binomial probabilities.
**One-sided 97.5% confidence interval based on binomial probabilities.
***The adjusted assumes that one case of a high-grade lesion was misclassified as normal by both types of specimens.
doi:10.1371/journal.pone.0082115.t003
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